Analyst Price Target is $3.33
▲ +703.21% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Aprea Therapeutics in the last 3 months. The average price target is $3.33, with a high forecast of $4.00 and a low forecast of $3.00. The average price target represents a 703.21% upside from the last price of $0.42.
Current Consensus is
The current consensus among 3 investment analysts is to buy stock in Aprea Therapeutics. This rating has held steady since August 2022, when it changed from a Hold consensus rating.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.